Alaunos Therapeutics, Inc. TCRT
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) is a cardio-renal-metabolic drug developer. Its lead program, ALN1003, is in Pre-clinical for obesity and metabolic disorders (MASLD, insulin resistance). Its next catalyst on record is VLR199: Alaunos, after acquiring Velaris and a $350M private placement, expects clinical proof-of-concept data for VLR199 (ActRIIA-Fc ligand trap, PAH) in 2028. (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VLR199 — Alaunos, after acquiring Velaris and a $350M private placement, expects clinical proof-of-concept data for VLR199 (ActRIIA-Fc ligand trap, PAH) in 2028. (2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TCR-T Library (legacy, discontinued Aug 2023) | solid tumors | cell therapy | Phase 1 |
| ALN1003 | obesity / MASLD | small molecule | Pre-clinical |
Recent results and decisions
- Oct 14, 2026n/a Alaunos completed $350 million private placement financing with gross proceeds from sale of common stock and Series C preferred stock.
On October 14, 2026, the Company completed the Financing and received aggregate gross proceeds of approximately $350.0 million, before deducting placement agent fees and other offering expenses.
Filing - Oct 13, 2026n/a Alaunos completed its acquisition of Velaris Therapeutics.
On October 13, 2026, the Company completed its acquisition of Velaris Therapeutics, Inc. pursuant to an Agreement and Plan of Merger, dated as of October 13, 2026.
Filing - Oct 5, 2026n/a Alaunos Therapeutics received notice of potential delisting from Nasdaq for non-compliance with stockholders' equity requirement, with hearing scheduled for November 10, 2026.
On October 5, 2026, received a written notice from the Staff informing the Company that its securities were subject to delisting from Nasdaq due to its continued non-compliance with the Stockholders' Equity Requirement unless the Company timely requested a hearing before the Nasdaq Hearings Panel.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
- Opko Health, Inc. OPK
- Editas Medicine, Inc. EDIT
- Atrium Therapeutics, Inc. RNA
- Cellectis S.A. CLLS
- NewcelX Ltd. NCEL
- Fractyl Health, Inc. GUTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.